GoodRx Holdings, Inc.
GDRX
$4.48
$0.0050.11%
| Weiss Ratings | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.64 | |||
| Price History | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -9.41% | |||
| 30-Day Total Return | -9.60% | |||
| 60-Day Total Return | -4.99% | |||
| 90-Day Total Return | -26.88% | |||
| Year to Date Total Return | -1.86% | |||
| 1-Year Total Return | -33.90% | |||
| 2-Year Total Return | -29.53% | |||
| 3-Year Total Return | -67.14% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -51.73% | |||
| 52-Week Low % Change | 9.29% | |||
| Price | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.26 | |||
| 52-Week Low Price | $4.09 | |||
| 52-Week Low Price (Date) | Nov 15, 2024 | |||
| 52-Week High Price (Date) | Jul 25, 2024 | |||
| Valuation | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.71B | |||
| Enterprise Value | 1.81B | |||
| Price/Earnings (TTM) | 104.20 | |||
| Earnings Per Share (TTM) | 0.04 | |||
| Earnings Per Share Growth | -269.57% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.16 | |||
| Price/Book (Q) | 2.36 | |||
| Enterprise Value/Revenue (TTM) | 2.28 | |||
| Price | $4.48 | |||
| Enterprise Value/EBITDA (TTM) | 11.83 | |||
| Enterprise Value/EBIT | 18.24 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 383.58M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 855 268 2822 | |||
| Address | 2701 Olympic Boulevard Santa Monica, CA 90404 | |||
| Website | www.goodrx.com | |||
| Country | United States | |||
| Year Founded | 2011 | |||
| Profitability | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 12.52% | |||
| Profit Margin | 2.06% | |||
| Management Effectiveness | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 4.17% | |||
| Return on Equity | 2.21% | |||
| Income Statement | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 792.32M | |||
| Total Revenue (TTM) | 792.32M | |||
| Revenue Per Share | $2.07 | |||
| Gross Profit (TTM) | 744.11M | |||
| EBITDA (TTM) | 152.98M | |||
| EBIT (TTM) | 99.20M | |||
| Net Income (TTM) | 16.39M | |||
| Net Income Avl. to Common (TTM) | 16.39M | |||
| Total Revenue Growth (Q YOY) | 0.99% | |||
| Earnings Growth (Q YOY) | 126.05% | |||
| EPS Diluted (TTM) | 0.04 | |||
| EPS Diluted Growth (Q YOY) | 127.57% | |||
| Balance Sheet | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 448.35M | |||
| Cash Per Share (Q) | $1.17 | |||
| Total Current Assets (Q) | 659.26M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 724.66M | |||
| Current Ratio (Q) | 5.321 | |||
| Book Value Per Share (Q) | $1.89 | |||
| Total Assets (Q) | 1.39B | |||
| Total Current Liabilities (Q) | 123.90M | |||
| Total Debt (Q) | 543.39M | |||
| Total Liabilities (Q) | 663.41M | |||
| Total Common Equity (Q) | 724.66M | |||
| Cash Flow | GDRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -70.35M | |||
| Cash from Financing (TTM) | -337.50M | |||
| Net Change in Cash (TTM) | -223.95M | |||
| Levered Free Cash Flow (TTM) | 124.90M | |||
| Cash from Operations (TTM) | 183.89M | |||
